137 related articles for article (PubMed ID: 36451169)
21. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A
J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139
[TBL] [Abstract][Full Text] [Related]
22. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
23. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
Wu YL; Zhang L; Kim DW; Liu X; Lee DH; Yang JC; Ahn MJ; Vansteenkiste JF; Su WC; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan DSW
J Clin Oncol; 2018 Nov; 36(31):3101-3109. PubMed ID: 30156984
[TBL] [Abstract][Full Text] [Related]
24. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
25. Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity.
Takimoto T; Kijima T; Otani Y; Nonen S; Namba Y; Mori M; Yokota S; Minami S; Komuta K; Uchida J; Imamura F; Furukawa M; Tsuruta N; Fujio Y; Azuma J; Tachibana I; Kumanogoh A
Clin Lung Cancer; 2013 Sep; 14(5):502-7. PubMed ID: 23664723
[TBL] [Abstract][Full Text] [Related]
26. ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib.
Sakamoto S; Sato K; Takita Y; Izumiya Y; Kumagai N; Sudo K; Hasegawa Y; Yokota H; Akamine Y; Okuda Y; Asano M; Takeda M; Sano M; Miura M; Nakayama K
Invest New Drugs; 2020 Dec; 38(6):1687-1695. PubMed ID: 32436059
[TBL] [Abstract][Full Text] [Related]
27. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
[TBL] [Abstract][Full Text] [Related]
28. Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.
Liu K; Jiang G; Zhang A; Li Z; Jia J
BMC Cancer; 2020 Jan; 20(1):76. PubMed ID: 32000711
[TBL] [Abstract][Full Text] [Related]
29. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
Swaisland HC; Cantarini MV; Fuhr R; Holt A
Clin Pharmacokinet; 2006; 45(6):633-44. PubMed ID: 16719544
[TBL] [Abstract][Full Text] [Related]
30. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
[TBL] [Abstract][Full Text] [Related]
31. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).
Tamura K; Okamoto I; Kashii T; Negoro S; Hirashima T; Kudoh S; Ichinose Y; Ebi N; Shibata K; Nishimura T; Katakami N; Sawa T; Shimizu E; Fukuoka J; Satoh T; Fukuoka M;
Br J Cancer; 2008 Mar; 98(5):907-14. PubMed ID: 18283321
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy and Safety of Gefitinib as First-Line Chemotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer(NSCLC)].
Ohashi K; Takamori M; Takahashi Y; Kawai S; Yamamoto M; Kitazono M; Murata K; Wada A
Gan To Kagaku Ryoho; 2019 Jan; 46(1):55-59. PubMed ID: 30765643
[TBL] [Abstract][Full Text] [Related]
33. Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience.
Oda N; Hotta K; Yoshioka H; Kudo K; Ichihara E; Kato Y; Ninomiya K; Minami D; Ninomiya T; Kubo T; Ohashi K; Sato A; Takigawa N; Tabata M; Tanimoto M; Kiura K
Cancer Chemother Pharmacol; 2016 Nov; 78(5):941-947. PubMed ID: 27590708
[TBL] [Abstract][Full Text] [Related]
34. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
Inoue A; Yoshida K; Morita S; Imamura F; Seto T; Okamoto I; Nakagawa K; Yamamoto N; Muto S; Fukuoka M
Jpn J Clin Oncol; 2016 May; 46(5):462-7. PubMed ID: 26977054
[TBL] [Abstract][Full Text] [Related]
35. Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities.
Kwok WC; Lam DCL; Ip MSM; Tam TCC; Ho JCM
Anticancer Drugs; 2022 Nov; 33(10):1139-1144. PubMed ID: 35946566
[TBL] [Abstract][Full Text] [Related]
36. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.
Oizumi S; Kobayashi K; Inoue A; Maemondo M; Sugawara S; Yoshizawa H; Isobe H; Harada M; Kinoshita I; Okinaga S; Kato T; Harada T; Gemma A; Saijo Y; Yokomizo Y; Morita S; Hagiwara K; Nukiwa T
Oncologist; 2012; 17(6):863-70. PubMed ID: 22581822
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
Mizoguchi K; Nakamura Y; Sano K; Sato S; Ikegami Y; Motoshima K; Takemoto S; Ogawara D; Senju H; Sugasaki N; Ikeda T; Yamaguchi H; Nakatomi K; Fukuda M; Izumikawa K; Mukae H
Cancer Chemother Pharmacol; 2016 Aug; 78(2):377-82. PubMed ID: 27339148
[TBL] [Abstract][Full Text] [Related]
38. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Mitsudomi T; Morita S; Yatabe Y; Negoro S; Okamoto I; Tsurutani J; Seto T; Satouchi M; Tada H; Hirashima T; Asami K; Katakami N; Takada M; Yoshioka H; Shibata K; Kudoh S; Shimizu E; Saito H; Toyooka S; Nakagawa K; Fukuoka M;
Lancet Oncol; 2010 Feb; 11(2):121-8. PubMed ID: 20022809
[TBL] [Abstract][Full Text] [Related]
39. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
Ichihara E; Hotta K; Takigawa N; Kudo K; Kato Y; Honda Y; Hayakawa H; Minami D; Sato A; Tabata M; Tanimoto M; Kiura K
Lung Cancer; 2013 Sep; 81(3):435-439. PubMed ID: 23809059
[TBL] [Abstract][Full Text] [Related]
40. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
Asahina H; Yamazaki K; Kinoshita I; Sukoh N; Harada M; Yokouchi H; Ishida T; Ogura S; Kojima T; Okamoto Y; Fujita Y; Dosaka-Akita H; Isobe H; Nishimura M
Br J Cancer; 2006 Oct; 95(8):998-1004. PubMed ID: 17047648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
